Inflammatory bowel disease, Ulcerative colitis
SYRESpyre Therapeutics IncCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for SPY002 (SPY002-091) (TL1A) in Inflammatory bowel disease, Ulcerative colitis. The expected timing is based on the latest available company guidance and may change.
03/16/26:- SKYLINE UC platform enrolling ahead of schedule; Part A readouts begin Q2 2026. 04/13/26:- SKYLINE Part A induction data expected Mid-2026. Part B induction data remains on track for 2027. 05/05/26:- SPY002 Phase 1 safety and PK data favorable with durable TL1A suppression. SKYLINE Part A induction data Mid-2026. 06/03/26:- SKYLINE Part A now fully enrolled. Part A induction data remains expected in Mid-2026. 06/15/26:- Positive Ph2 SKYLINE Part A induction topline; met primary endpoint. Part B now enrolling. 08/04/26:- SKYLINE SPY002 data detailed; Part B induction data expected 2027.
Verification
Confirm timing and program details against the company announcement or filing.